SpyBiotech
Generated by Meeveem AI
"Clinical stage biotech using protein superglue technology to develop infectious disease vaccines."
Oxford
•11 - 50 Employees
•Biotechnology
About SpyBiotech
SpyBiotech develops vaccines using its proprietary SpyTag SpyCatcher protein superglue technology, a platform designed to trigger immune responses against infectious diseases and cancer. The company's lead candidate, SPYVLP01, targets cytomegalovirus and is advancing through Phase I clinical trials with demonstrated safety and immunogenicity. Founded as a University of Oxford spin out in 2017, SpyBiotech combines validated science with clinical momentum to address diseases with significant unmet medical need. The platform enables rapid vaccine development across viral, bacterial, parasitic, and therapeutic applications, supported by partnerships including licensing agreements for COVID 19 and Epstein Barr virus vaccines.
23
Team Members
2017
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A world where protein superglue technology enables rapid, safe, and effective vaccines for diseases that currently lack solutions.
Our Mission
At SpyBiotech, our mission is to leverage the unique benefits of the SpyTag SpyCatcher platform to address major human health challenges and develop safe and highly effective vaccines with greater ease and speed.